Debbie Rigby covers the latest research relevant to pharmacists
This study represents the first evaluation of the relative benefits of onabotulinumtoxinA compared with mirabegron in adults with idiopathic overactive bladder. An indirect comparison indicates that onabotulinumtoxinA may be superior to mirabegron in improving symptoms of urinary incontinence, urgency and urinary frequency in patients with idiopathic OAB.
BMJ Open 2016;6:e009122.
A systematic review and meta-analyses by Australian researchers have concluded that pharmacist-led medication reconciliation programmes are effective at improving post-hospital healthcare utilisation. The pooled relative risks showed a more substantial reduction in adverse drug event-related hospital revisits (RR 0.33), emergency department visits (RR 0.72) and hospital readmissions (RR 0.81) in the intervention group than in the usual care group, respectively.
BMJ Open 2016;6:e010003.
An open label randomised controlled trial of more than 500 patients in the UK has shown that active management of systolic blood pressure in people with a history of stroke or transient ischaemic attack using a <140 mm Hg target led to a clinically important reduction in blood pressure. Participants had a baseline systolic blood pressure of 125 mm Hg or above.
A prospective study and meta-analysis has shown that chocolate consumption is associated with a 10% lower risk of MI and ischaemic heart disease. High chocolate consumption, defined as >50g/week, was associated with a significant 13% reduced risk of MI and a significant 10% lower risk of IHD. A beneficial effect of chocolate consumption on risk of MI/IHD is biologically plausible as chocolate or cocoa significantly improves insulin sensitivity and endothelial function, and reduces fasting insulin concentration, diastolic blood pressure and mean arterial pressure. Chocolate or cocoa flavanol intake was also found to increase high-density lipoprotein cholesterol and to decrease low-density lipoprotein cholesterol and triglycerides.